<DOC>
	<DOCNO>NCT02844881</DOCNO>
	<brief_summary>The study aim evaluate efficacy safety Apatinib MASCT patient advance solid tumor .</brief_summary>
	<brief_title>Study Apatinib MASCT Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Angiogenesis hallmark cancer , together vascular endothelial growth factor ( VEGF ) one important angiogenic driver . Inhibitors target VEGF/VEGFR-pathway show beneficial effect many cancer patient , transient follow fast regrowth . Similarly , effectiveness tumor immunotherapy limit tumor-mediated escape mechanism immune suppression . By combine two strategy , antiangiogenic immunotherapy offer possibility vigorously inhibit tumor angiogenesis promote endure immune-stimulatory milieu lead prolong survival benefit cancer patient . Apatinib small-molecule tyrosine kinase inhibitor ( TKI ) highly selectively bind strongly inhibit vascular endothelial growth factor receptor 2 ( VEGFR-2 ) . Apatinib demonstrate monotherapy prolongs OS patient gastric gastroesophageal junction adenocarcinoma two line chemotherapy moderate , reversible , easily manage adverse event . Multiple antigens specific cellular therapy ( MASCT ) new immunotherapy dendritic cell ( DC ) induce autologous peripheral blood . The DC load 17 antigen re-infused . In vitro , antigen-pulsed DC stimulate autologous T-cell proliferation induction autologous specific cytotoxic T-cells ( CTL ) ，similarly re-infused . The previous research data show MASCT modest overall response less adverse effect Hepatocellular Carcinoma patient . The study aim evaluate efficacy safety Apatinib MASCT patient advance solid tumor .</detailed_description>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<criteria>1 . Patients histologicallyconfirmed , advance ( unresectable ) solid tumor progress standard therapy . 2 . With write informed consent sign voluntarily patient . 3 . The time Patients enrollment end antitumors therapies≤1 month 4 . Eastern Cooperative Oncology Group Performance Status ( ECOG P.S . ) ≤ 2 5 . At least one measurable lesion define RECIST criterion 1.1 solid tumor . 6 . Life expectancy ≥6 month . 7 . With normal cardiopulmonary function . 8 . Patients adequate organ function define follow criterion : Hemoglobin ( HGB ) ≥85g/L Absolute neutrophil count ( ANC ) ≥1.0×109/L White blood cell ( WBC ) ≥3.0×109/L Platelet count ≥50×109/L Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≤2.5 upper normal limitation ( UNL ) ≤5 UNL case liver metastasis Alkaline phosphatase ( ALP ) ≤2.5 UNL Total bilirubin ( TBil ) ≤1.5 UNL Blood urea nitrogen ( BUN ) Creatinine ( Cr ) of≤1.5 UNL Albumin ( ALB ) ≥30g/L 1 . Pregnant expect pregnant 2 . Participated clinical trial screen except observational study . 3 . Known allergic history sodium citrate drug . 4 . Known history organ transplant , include autologous bone marrow transplantation peripheral stem cell transplantation . 5 . Known active brain metastasis determine CT MRI evaluation . 6 . The use immunosuppressive drug current 14 day enrollment . 7 . Know period systemic continuous use immunomodulatory agent ( interferon , thymosin , traditional Chinese medicine ) within 6 month . 8 . Prior therapy antiprogrammed death1 ( antiPD1 ) , antiprogrammed cell death ligand 1 ( antiPDL1 ) , antiCytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) antibody ( include antibody drug specifically target Tcell costimulation ) . 9 . Known history primary immunodeficiency disease . 10 . Known history tuberculosis . 11 . Known active human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C. 12 . Patients serious infection , hepatopathy , nephropathy , respiratory disease , cardiovascular disease incontrollable diabetes , etc . 13 . Patients malignant tumor within 5 year , exclude melanoma carcinoma situ cervix . 14 . Treatment antitumors agent within 28days first administration study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>